GSK Investigational Site
Middlebury, Connecticut 06762
We've found
5 trials
at this facility
Anemia Clinical Trial
Updated: 3/31/2016
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia
Status: Enrolling,
Phase
II
Updated: 3/31/2016
Click here to add this to my saved trials
Anaemia Clinical Trial
Updated: 12/31/1969
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Anaemia Clinical Trial
Updated: 12/31/1969
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Anaemia Clinical Trial
Updated: 12/31/1969
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Anaemia Clinical Trial
Updated: 12/31/1969
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials